Jeffrey T. Hajibandeh, D.D.S., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Orbital Fractures | 3 | 2023 | 108 | 2.200 |
Why?
|
| Orbital Implants | 2 | 2022 | 20 | 1.560 |
Why?
|
| Surgery, Oral | 2 | 2022 | 133 | 1.160 |
Why?
|
| Maxillofacial Injuries | 1 | 2023 | 32 | 0.850 |
Why?
|
| Mandibular Fractures | 4 | 2024 | 77 | 0.760 |
Why?
|
| Orbit | 3 | 2023 | 458 | 0.470 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2022 | 994 | 0.460 |
Why?
|
| Palatal Neoplasms | 1 | 2014 | 37 | 0.440 |
Why?
|
| Palate, Soft | 1 | 2014 | 100 | 0.430 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2014 | 79 | 0.430 |
Why?
|
| Dental Implants | 1 | 2021 | 790 | 0.420 |
Why?
|
| Checklist | 1 | 2017 | 837 | 0.340 |
Why?
|
| Medical Errors | 1 | 2017 | 1257 | 0.320 |
Why?
|
| Immunocompromised Host | 1 | 2014 | 866 | 0.300 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1434 | 0.220 |
Why?
|
| Trauma Centers | 3 | 2023 | 950 | 0.200 |
Why?
|
| Neck Injuries | 1 | 2023 | 162 | 0.190 |
Why?
|
| Facial Injuries | 1 | 2023 | 190 | 0.190 |
Why?
|
| Craniocerebral Trauma | 1 | 2023 | 493 | 0.160 |
Why?
|
| Temporomandibular Joint Disorders | 1 | 2020 | 226 | 0.140 |
Why?
|
| Workflow | 1 | 2021 | 857 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2022 | 789 | 0.120 |
Why?
|
| Emergency Service, Hospital | 3 | 2024 | 7872 | 0.120 |
Why?
|
| Periodontium | 1 | 2014 | 99 | 0.110 |
Why?
|
| Athletic Injuries | 1 | 2023 | 1244 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2023 | 2513 | 0.090 |
Why?
|
| Vitamin B Complex | 1 | 2010 | 299 | 0.080 |
Why?
|
| Retrospective Studies | 8 | 2024 | 81505 | 0.070 |
Why?
|
| Humans | 17 | 2024 | 765823 | 0.070 |
Why?
|
| Tissue Scaffolds | 1 | 2014 | 934 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 2169 | 0.070 |
Why?
|
| Hospitalization | 2 | 2024 | 10803 | 0.070 |
Why?
|
| Telemedicine | 1 | 2023 | 3106 | 0.060 |
Why?
|
| Mouth Neoplasms | 1 | 2010 | 594 | 0.060 |
Why?
|
| Regeneration | 1 | 2014 | 1516 | 0.060 |
Why?
|
| Tissue Engineering | 1 | 2014 | 1855 | 0.060 |
Why?
|
| Folic Acid | 1 | 2010 | 1337 | 0.050 |
Why?
|
| Young Adult | 4 | 2024 | 59849 | 0.050 |
Why?
|
| United States | 5 | 2024 | 72896 | 0.050 |
Why?
|
| Bicycling | 1 | 2023 | 176 | 0.050 |
Why?
|
| Adolescent | 4 | 2024 | 88794 | 0.050 |
Why?
|
| Facial Bones | 1 | 2022 | 208 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 2945 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 223016 | 0.040 |
Why?
|
| Temporomandibular Joint | 1 | 2020 | 201 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 12966 | 0.040 |
Why?
|
| Child | 2 | 2023 | 80509 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20680 | 0.040 |
Why?
|
| Length of Stay | 2 | 2022 | 6485 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2010 | 3425 | 0.040 |
Why?
|
| Patient Admission | 1 | 2024 | 1364 | 0.030 |
Why?
|
| Face | 1 | 2022 | 1028 | 0.030 |
Why?
|
| Triage | 1 | 2023 | 994 | 0.030 |
Why?
|
| Quality Improvement | 2 | 2021 | 3845 | 0.030 |
Why?
|
| Adult | 4 | 2024 | 223055 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 4046 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2022 | 15794 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10428 | 0.030 |
Why?
|
| Amelogenin | 1 | 2014 | 14 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2014 | 91 | 0.030 |
Why?
|
| Calcification, Physiologic | 1 | 2014 | 166 | 0.030 |
Why?
|
| Dental Pulp | 1 | 2014 | 80 | 0.030 |
Why?
|
| Outpatients | 1 | 2021 | 1591 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2024 | 1946 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2014 | 343 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2024 | 2521 | 0.020 |
Why?
|
| Risk Factors | 3 | 2022 | 74853 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2010 | 276 | 0.020 |
Why?
|
| Recurrence | 1 | 2020 | 8506 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2021 | 3284 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2014 | 12767 | 0.020 |
Why?
|
| HIV Infections | 1 | 2014 | 17530 | 0.020 |
Why?
|
| Logistic Models | 1 | 2021 | 13266 | 0.020 |
Why?
|
| Aged | 3 | 2024 | 171178 | 0.020 |
Why?
|
| Collagen | 1 | 2014 | 2617 | 0.020 |
Why?
|
| Male | 3 | 2024 | 363740 | 0.020 |
Why?
|
| Phenotype | 2 | 2014 | 16706 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 26276 | 0.010 |
Why?
|
| Stem Cells | 1 | 2014 | 3539 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 4249 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2021 | 24278 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 10723 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2014 | 18970 | 0.010 |
Why?
|
| Cell Line | 1 | 2010 | 15540 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2022 | 65223 | 0.010 |
Why?
|
| Female | 2 | 2024 | 396050 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 17063 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 81788 | 0.000 |
Why?
|
| Animals | 1 | 2014 | 168730 | 0.000 |
Why?
|